Trials / Completed
CompletedNCT03441581
Eluxadoline Bile Acid Malabsorption (BAM) Study
3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eluxadoline | Eluxadoline 100 mg oral tablets BID with food. |
Timeline
- Start date
- 2018-02-23
- Primary completion
- 2020-04-28
- Completion
- 2020-04-28
- First posted
- 2018-02-22
- Last updated
- 2021-05-19
- Results posted
- 2021-05-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03441581. Inclusion in this directory is not an endorsement.